AllergyTalk
AllergyTalk delivers the latest insights and evidence shaping allergy and immunology. In each bimonthly episode, leading experts break down the most impactful research and real-world takeaways from AllergyWatch®, a bimonthly publication summarizing key findings from 20 major journals in allergy and asthma.
Listen on:
Episodes
Friday Dec 13, 2024
Friday Dec 13, 2024
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI
This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed.
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Diagnose pediatric HAE accurately
References:
Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022
Speaker Disclosures:
Kristin C. Sokol, MD, MS, MPH, FACAAI
Advisor: Sanofi, Genentech, SELF/Conde Nast
Aleena Banerji, MD
Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda
Researcher: Astria, Ionis, Intellia
Timothy J. Craig, DO, FACAAI
Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda
Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda
Independent Contractor: Kalvista, Phavaris
Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda
Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda
This podcast miniseries is supported by a grant from Takeda.
Friday Dec 13, 2024
Friday Dec 13, 2024
Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!
For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
CRISPR Gene-Editing Therapy for Hereditary Angioedema
Reviewed by Samantha knox
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.
Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, Seitzer J, Han BW, Soukamneuth S, Leonard J, Sepp-Lorenzino L, Clark ED, Lebwohl D, Cohn DM. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024 Feb 1;390(5):432-441. doi: 10.1056/NEJMoa2309149. PMID: 38294975.
New Peanut Allergy Rare After Peanut Introduction in Infants
Reviewed by Sarah Spriet
Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants
Banerjee A, Wood R, Dunlop J, Dantzer J, Plesa M, Togias A, Keet C. Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants. J Allergy Clin Immunol Pract. 2024 Mar;12(3):645-651.e1. doi: 10.1016/j.jaip.2023.11.035. Epub 2023 Nov 29. PMID: 38036248.
IgE to Food Allergens and Cardiovascular Mortality
Reviewed by Gerry Lee
IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis
Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A, Wilson JM. IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. J Allergy Clin Immunol. 2024 Feb;153(2):471-478.e3. doi: 10.1016/j.jaci.2023.09.038. Epub 2023 Nov 9. PMID: 37943208; PMCID: PMC10922097.
Please rate our podcast on Apple podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis
Dr. Fineman has nothing to disclose
Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended KA)
Friday Dec 13, 2024
Friday Dec 13, 2024
Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!
For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Reviewed by Iris Otani
Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial.
Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839.
Clinical Remission in a Real-World Severe Asthma Registry
Reviewed by Tim Chow
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.
McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453.
More Evidence Against Using Corticosteroids for Anaphylaxis
Reviewed by Iris Otani
Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data.
Delli Colli L, Al Ali A, Gabrielli S, Delli Colli M, Mule P, Lawson B, Clarke AE, Morris J, Gravel J, Lim R, Chan ES, Goldman RD, O'Keefe A, Gerdts J, Chu DK, Upton J, Hochstadter E, Bretholz A, McCusker C, Zhang X, Benor S, Simons E, Abrams EM, Protudjer JLP, Ben-Shoshan M. Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Ann Allergy Asthma Immunol. 2023 Dec;131(6):752-758.e1. doi: 10.1016/j.anai.2023.08.606. Epub 2023 Sep 7. PMID: 37689113.
Please rate our podcast on Apple podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis
Dr. Fineman has nothing to disclose
Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended)
Thursday Oct 17, 2024
Thursday Oct 17, 2024
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma
Host: Gerald B. Lee, MD, FACAAI
Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.
Learning Objectives:
Expose the prevalence of asthma and exacerbations in the US
Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
Reference:Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.
Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
Leonard B. Bacharier, MD, FACAAI
Advisor: DBV Technologies
Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca, Sanofi
Speaker: Regeneron, Sanofi
Alan P. Baptist, MD, MPH, FACAAI
Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Researcher: AstraZeneca, Novartis, Regeneron
This podcast miniseries is supported by a grant from AstraZeneca.
Thursday Oct 17, 2024
Thursday Oct 17, 2024
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma
Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.
Learning Objectives:
Expose the prevalence of asthma and exacerbations in the US
Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.
Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi
Leonard B. Bacharier, MD, FACAAI
Advisor: DBV Technologies
Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca, Sanofi
Speaker: Regeneron, Sanofi
This podcast miniseries is supported by a grant from AstraZeneca.
Thursday Oct 17, 2024
Thursday Oct 17, 2024
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 1: The Limitations of Bronchodilator Only Rescue Therapy
Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.
Learning Objectives:
Expose the prevalence of asthma and exacerbations in the US
Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.
Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi
Alan P. Baptist, MD, MPH, FACAAI
Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Researcher: AstraZeneca, Novartis, Regeneron
This podcast miniseries is supported by a grant from AstraZeneca.
Wednesday Sep 11, 2024
Wednesday Sep 11, 2024
Welcome to Season Three of Allergytalk!
Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Gut microbiota maturity mediates the protective effect of siblings on food allergy.
Duration of skin prick test refractory period following food-induced allergic reactions.
Clinical and immunological phenotypes of selective IgM deficiency in children: Results from a multicenter study.
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt
Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
Wednesday Sep 11, 2024
Wednesday Sep 11, 2024
Welcome to Season Three of Allergytalk!
Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Outcomes of oral food challenges in a real-world setting, with predictors of outcomes.
Severe food allergy reactions are associated with α-tryptase.
Association of a Housing Mobility Program With Childhood Asthma Symptoms and Exacerbations.
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt
Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
Wednesday Aug 14, 2024
Wednesday Aug 14, 2024
Welcome to a Special Board Review Episode of AllergyTalk!
As the fall welcomes a new class of allergy/immunology fellows, the graduating fellows are studying for the fall ABAI board certification exam. I’m excited to be joined by the editorial team of the newly released 5th edition of the ACAAI Review of the Allergy & Immunology Boards, where we’ll talk about how you can prepare for the upcoming board exam!
Guests:
Joyce Yu, MDAssociate Professor of PediatricsDirector, Food Allergy CenterDivision of Allergy, Immunology and RheumatologyColumbia University Irving Medical Center
Ben Prince, MD, MSCIAssociate Professor of PediatricsAssociate Division Chief of ResearchDivision of Allergy-ImmunologyThe Ohio State University College of Medicine
Resources for Board Review:
Exam Blueprint
ACAAI FIT and Board Review Resources (including the board review book)
AIM Self-Assessment: Volume One (2023)
AAAAI Allergy/Immunology Self Assessment
For information about CME credit, head over to http://education.acaai.org/allergytalk
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Prince is a Data Monitoring Committee Member for Eli Lilly
Dr. Yu has no relevant disclosures.
Tuesday Jul 16, 2024
Tuesday Jul 16, 2024
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.
Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
Prevalence of CFTR variants in primary immunodeficiency patients with bronchiectasis is an important modifying cofactor.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Spriet have nothing to disclose
Dr. Fineman: Research: DBV, Novartis, Alladapt